Civitas Therapeutics is developing breakthrough therapies that transcend the historic limits of respiratory drug delivery with its therapeutic platform. The clinically validated ARCUS® technology uniquely enables respiratory delivery of a large, precise dose with a simple, convenient, breath activated device as demonstrated by Civitas’ lead program. CVT-301 is being developed as an on-demand (PRN) therapy for intermittent, debilitating and unpredictable OFF episodes associated with Parkinson’s disease. With CVT-301, patients will be able to treat their OFF episodes as their symptoms begin to emerge with a simple inhalation, dramatically improving control of their symptoms and allowing them to lead more productive and independent lives. In October 2014, Civitas was acquired by Acorda Therapeutics (NASDAQ:ACOR).
Civitas Therapeutics
